# Award Number: W81XWH-06-1-0458

#### TITLE:

Characterizing the Role of 1p36 Deletion in Breast Cancer and Identifying Candidate Tumor Suppressors

PRINCIPAL INVESTIGATOR: Christopher S. Hackett

CONTRACTING ORGANIZATION:

University of California, San Francisco

San Francisco, CA 94143

REPORT DATE:

April 2009

TYPE OF REPORT:

Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

### DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# **REPORT DOCUMENTATION PAGE**

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY)	2. REPORT TYPE	3. DATES COVERED (From - To)
01-04-2009	Annual Summary	1 APR 2006 - 31 MAR 2009
4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER	
Characterizing the Role of		
		5b. GRANT NUMBER
Cancer and Identifying Canc	W81XWH-06-1-0458	
	5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Christopher S. Hackett		5d. PROJECT NUMBER
•		5e. TASK NUMBER
Email: chris.hackett@ucsf.edu	5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S	S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT
University of California, San Fra San Francisco, CA 94143	ncisco	NUMBER
A SPONSOPING / MONITORING AGENCY	NAME(C) AND ADDRESS(ES)	40. CDONCOD/MONITORIC ACDONYM/C)
9. SPONSORING / MONITORING AGENCY U.S. Army Medical Research	NAME(5) AND ADDRESS(E5)	10. SPONSOR/MONITOR'S ACRONYM(S)
and Materiel Command		
Fort Detrick, Maryland		11. SPONSOR/MONITOR'S REPORT
21702-5012		NUMBER(S)

### 12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

#### 13. SUPPLEMENTARY NOTES

14. ABSTRACT Subject: Over 60% of human breast tumors display a deletion of one copy of the 1p36 region of the short arm of chromosome 1. Patients whose tumors carry this deletion show a three-fold increase in mortality, suggesting a biological role for this deletion in tumor development, and suggesting the presence of one or more tumor suppressors in this region. Purpose: Characterization of the unique biology of tumors with 1p36 deletion, and identification of the tumor suppressor(s) in the region may inform therapeutic strategies, and present unique therapeutic targets for this subset of breast cancer cases with relatively poor survival. Scope: The goals of this research project are to 1) develop a mouse model for 1p36 deletion in breast cancer by generating mice harboring loxP sequences flanking the deletion region, and crossing to tissue-specific Cre expressing mice, 2) perform in-vivo insertional mutagenesis in breast tumors using the two-component Sleeping Beauty transposon system (mutagenic transposons mobilized by a trans-acting transposase) to tag tumor suppressors and oncogenes during tumor development and 3) to combine these two systems to identify tumor suppressors in the 1p36 region. Technical setbacks and the observation by another group that deletion of at least part of the 1p36 region systemically does not lead to breast tumors in mice have led us to focus primarily on the Sleeping Beauty system for the last two years. We have opted for an in vitro approach in which we use lentiviral constructs to activate transposons in mammary epithelial cells, which we then transplant into recipient mice.

#### 15. SUBJECT TERMS

1p36, insertional mutagenesis, sleeping beauty, mouse models, tumor suppressors

16. SECURITY CLASSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT U	b. ABSTRACT	<b>c. THIS PAGE</b> U	טט	10	19b. TELEPHONE NUMBER (include area code)

# **Table of Contents**

	<u>Page</u>
Introduction	4
Body	4
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusion	10
References	10
Appendices	10

**FINAL STATUS REPORT:** BC050930 Characterizing the Role of 1 p36 Deletion in Breast Cancer and Identifying Candidate Tumor Suppressors

**INTRODUCTION:** Subject: Over 60% of human breast tumors display a deletion of one copy of the 1p36 region of the short arm of chromosome 1. Patients whose tumors carry this deletion show a threefold increase in mortality, suggesting a biological role for this deletion in tumor development, and suggesting the presence of one or more tumor suppressors in this region. **Purpose:** Characterization of the unique biology of tumors with 1p36 de letion, and identification of the tumor suppressor(s) in the region may inform therapeutic strategies, and present unique therapeutic targets for this subset of breast cancer cases with relatively poor survival. **Scope:** The goals of this research project are to 1) develop a mouse model for 1p36 de letion in breast cancer by generating mice harboring loxP sequences flanking the deletion region, and crossing to tissue-specific Cre expressing mice, 2) perform in-vivo insertional mutagenesis in breast tumors using the two-component Sleeping Beauty transposon system (mutagenic transposons mobilized by a trans-acting transposase) to tag tumor suppressors and oncogenes during tumor de velopment and 3) to c ombine these two systems to identify tumor suppressors in the 1p36 region. Technical setbacks and the observation by another group that deletion of at least part of the 1p36 region systemically does not lead to breast tumors in mice have led us to focus primarily on the Sleeping Beauty system for the last two years. While we have been able to map transposon insertions, we have established that existing mouse constructs were inadequate to drive or accelerate tumors in the mammary gland. We have therefore opted for an in vitro approach in which we use lentiviral constructs to activate transposons in mammary epithelial cells, which we then transplant into recipient mice.

**<u>BODY:</u>** Results from all Tasks from which we have outcomes to date from the approved Statement of Work are summarized below:

**Task 1:** Development of a mouse model for 1p36 deletion

**Aims 1A, 1B, and 1C:** Obtain and verify MICER loxP targeting clones flanking syntenic region of chromosome 4 corresponding to 1p36, generate targeted ES clones, and breed doubly-targeted mice:

As s tated in the a nnual s tatus r eports f or year one a nd t wo, e arly i nto t his project, another g roup published a study in which they constitutively deleted a 4 Mb region of mouse chromosome 4 within the 1p36 syntenic region (Bagchi, et al, 2007), screened mouse embryonic fibroblast cells, and identified a candidate t umor s uppressor in t he r egion, C HD5. While t his s creen c an be c riticized f or not be ing comprehensive in the genes screened and may not have included the region most frequently deleted in breast tumors, this was a significant result in the field. However, mice harboring this deletion have not developed breast tumors, which could suggest either the authors did not include the region most relevant to br east cancer, or t hat l oss of t his l ocus d oes not pr edispose cells in t he m ammary gland t o transformation. Additionally, since initiating this project, we established that the HPRT-GFP construct we had proposed to use was not functional, ne cessitating the cloning of a vector with an alternative marker (the V5 epitope). Furthermore, while cloning alternative targeting vectors, the mouse genome assembly at the telomeric end of mouse chromosome 4 has changed twice, each time ne cessitating a total refinement of our targeting strategy and setting us back several months as we cloned new targeting construct plasmids (detailed in the status reports from the first two years). The current assembly does not map an available BAC clone to the region containing the most telomeric genes, making it difficult to

clone a targeting vector that would allow us to delete all of the genes in the 1p36 locus. While we have ongoing e fforts to c lone a large genomic s equence us ing long-range PCR on genomic DNA as a template, we have not been successful to date. A dditionally, in summer 2008 my the sis committee concluded t hat, g iven the long t ime hor izon for this project and the numerous technical s etbacks experienced to date, I needed to focus on other aspects of my thesis project, most notably the Sleeping Beauty insertional mutagenesis approaches outlined in Task 3.

**Task 2:** Characterization of 1p36 deletion in the context of Her2-initiated oncogenesis: As stated last year, since initiation of Task 2 is dependent on completion of Task 1, it has not yet been initiated. However, we have initiated efforts to combine the S leeping Beauty's ystem (Task 3) with MMTV-HER2/neu and MMTV-c-myc induced mammary tumors, described below.

**Task 3:** Identification of candidate genes using insertional mutagenesis (months 15-36)

As described in previous reports, the Sleeping Beauty insertional mutagenesis system works via a two part m echanism: 1) a transposon (T2/Onc, T 2/Onc2, or T 2/Onc3), a D NA s equence capable of activating or deactivating surrounding host genes, and 2) a transposase protein (SB10 or SB11) which excises the T 2/Onc transposon and re-inserts it into a random location in the host genome. Cells harboring insertions conferring tumorigenic characteristics are selected and clonally expanded, allowing for identification of the insertion site and nearby genes.

We initially used the first-generation SB insertional mutagenesis system, consisting of a (presumably) constitutively expressed S B10 t ransposase und er t he c ontrol of a C AGGS (beta-actin) promoter. Transgenic mice harboring this construct and a transposon transgene did not succumb to tumors without a predisposing tumor suppressor knockout (Collier, et al, 2005). We combined this system with mice carrying the MMTV-HER2 transgene, susceptible to mammary tumors after a long latency. While we were able t o s uccessfully m ap t ransposon i nsertions, we did not observe a ny s ignificant t umor acceleration compared to mice carrying MMTV-HER2 a lone (described in the Annual Report from April 2008), nor did we see any transposase expression in tumors (described in the Annual Report from April 2007). The Largaespada group subsequently discovered that the CAGGS-SB10 c onstruct was only expressed in muscle tissue, most likely due to a positional effect at the transgene insertion site. Consistent with this, most of the insertion sites we were able to map in tumors were also present in spleens from the corresponding mice, suggesting the transposase was active early in development but dormant during tumor development.


We next at tempted to increase transposase activity using a Cre-activated Rosa-SB11 knock-in in combination with a high-copy transposon donor locus (T2/Onc2). We attempted to a ctivate this construct with an MMTV-Cre transgenic mouse. However, consistent with other groups, we observed a high rate of leukemia formation in these mice, suggesting that the MMTV-Cre construct was active in the hematopoietic compartment, where the SB system was much more effective at inducing tumors. Among the mice that did not succumb to leukemia, none developed breast cancer, in spite of the MMTV-HER2 transgene they carried. We speculate this resistance is derived from the mouse strain background; unlike the first generation SB system, which was on an FVB/N background susceptible to MMTV-HER2 induced tumors, the second and third (described below) generations are on a mixed, mostly B6, genetic background that shows less susceptibility to these tumors. In parallel, we combined

this system with the MMTV-c-myc model of mammary tumorigenesis. Mice in this model were even more prone to leukemia; while two mice in our screen developed solid tumors which were unlikely to have originated in the mammary gland, most mice carrying the constructs succumbed to leukemia. The high rate of leukemia in these mice prevented us from generating any reasonable collection of mammary tumors for insertion site analysis.

We next crossed MMTV-HER2 mice to mice carrying a constitutive RosaSB11 knock-in construct, in combination with low copy transposons (T2/Onc and T2/Onc3, which contains a different promoter). We hoped leukemia in these mice would be modest (Collier, et al, in review) and would allow for acceleration of mammary tumors. Unfortunately, we have only observed four tumors to date in mice carrying both transposon and transposase constructs and the MMTV-HER2 transgene, a rate too low to effectively identify common insertion sites. Additionally, we observed two tumors in mice carrying only one transposon/transposase component (i.e., negative controls), suggesting tumor acceleration may not be greatly enhanced by the transposon system. This particular conformation was also complicated by the genetic background issue described above.

In an attempt to overcome strain issues and leukemia incidence, we next turned to an in vitro/transplant based strategy. Briefly, in this system, mammary epithelial cells (MECs) are isolated from donor mice, in this case, mice carrying a dor mant transposon concatemer (T2/Onc, T2/Onc2, or T2/Onc3). These cells a recultured in vitro, and the SB transposase is then introduced with a viral vector. Virally-transduced cells are then transplanted into recipient mice in which the developing endogenous mammary epithelium has been surgically ablated. The transduced/transplanted MECs then repopulate the mammary fat gland, forming a normal branched ductal system, such that the mammary epithelium is genetically modified, but the surrounding tissue is wild-type.


We first tried to implement this system using MSCV-based retroviruses. As described in last year's report, cells is olated from MMTV-HER2;T2/Onc mice were transduced with a pM SCV-SB11-IRES-GFP (pMIG-SB11) and transplanted. Since these cells presumably had a growth advantage over normal cells (by virtue of the MMTV-HER2 transgene), endogenous epithelium was not a blated. While transplanted cells were viable (pictured in last year's report), we did not see the formation of fluorescent




ducts, nor did we see clear tumor formation i n t he t ransplanted mammary glands.

We next upgraded to a lentiviral-based system. Lentiviruses can infect non-dividing cells and thus can infect the mammary stem cell subpopulation in a MEC culture, providing more efficient outgrowth of transduced cells. Importantly, in this system (unlike the retroviral system),

transduced cells do not have to have a growth advantage to repopulate the mammary fat pad (Welm, et al 2008).



**Figure 2:** Expression of SB in 293T cells transduced with lentiviral constructs



**Figure 3:** Expression of fluorescent markers in lentivirally-transduced 293T cells.


We have cloned the SB11 transposase into two lentiviral constructs, pEIZ and pEIR (Welm, et al 2008) to make the constructs pEIZ-SB11 and pEIR-SB11 (Figure 1). T hese c onstruct express t he t ransposase (Figure 2) and fluorescent m arkers (Figure 3) in t ransduced 293T cells.

We then isolated MECs from mice carrying the high-copy T2/Onc2 transposon, as well as mice carrying the transposon on a p53<sup>+/-</sup> background. MECs were transduced with either control virus or SB11 virus at an MOI of 40. 300,000 cells were transplanted into cleared fat pads of 40 nude mice (20 receiving p53<sup>+/-</sup> cells and 20 receiving p53<sup>+/-</sup> cells) with the right gland receiving S B11-transduced cells and the left gland receiving vector-transduced cells. Forty

mice have been under observation for tumor formation for 6 m onths. A control mouse was dissected to establish that M ECs were reforming branched epithelials tructures; verification of the viability of these cells in comparison with wild-type glands and cleared fat pads is shown in Figure 4.

Should this s ystem prove to be effective at inducing tum ors, it will provide a powerful tool for further dissection of breast-cancer pathways, as cells from any transgenic or knockout donor mouse can be transduced and transplanted, and one 10-week-old donor mouse can generate enough cells to transplant into 10 recipient mice in a process that takes less than a week. We hope that the cohort of mice currently under observation will generate tumors at some point within the next 8-12 months, at which point we can perform

insertion site analysis and identify genes altered in multiple tumors and provide proof-of-principle that transposon-based insertional mutagenesis is possible in the mouse mammary gland.



**Figure 4:** Reconstitution of mammary epithelium with transplanted cells. **A:** Mammary gland from a 3-week old mouse. Mammary epithelial cells (red Carmine stain) grow from the left, and do not pass the lymph node (center-left red oval) by 3 weeks of age. **B:** By 8 weeks of age, branched mammary epithelial structures have grown throughout the entire gland. **C:** In glands in which the portion of the gland including the lymph node and everything to the left have been surgically removed, no mammary epithelium is present in the 8-week old gland. **D:** In glands in which the endogenous mammary epithelium has been removed as in (C), and mammary epithelial cells from a donor mouse (transduced in vitro) have been transplanted on the right edge, the transplanted cells grow out to form a normal-looking branched epithelial structure.

# **KEY RESEARCH ACCOMPLISHMENTS:**

- Generation of pEIZ-SB11 and pEIR-SB11 constructs.
- Successful clearing and reconstitution of mouse mammary glands.
- Generation of 20 T2/Onc2 pEIR-SB11 mice and 20 T2/Onc2;p53<sup>+/-</sup> mice

### **REPORTABLE OUTCOMES:**

Publications since award initiation:

- 1. Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender A, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, J. Hodgson G, Weiss WA, Jenkins RB, Largaespada DA. Whole-body Sleeping Beauty transponson mutagenesis can cause highly penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality or genomic instability (submitted)
- 2. Hackett C S, Geurts A M, Hackett PB. **Predicting preferential DNA vector insertion sites:** implications for functional genomics and gene therapy. Genome Biology 2007;8 Suppl 1:S12.
- 3. Cheng AJ, Ching Cheng N, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer. 2007 Apr 19
- 4. Geurts AM, Hackett CS, Bell JB, Bergemann TL, Collier LS, Carlson CM, Largaespada DA, Hackett PB. **Structure-based prediction of insertion-site preferences of transposons into chromosomes.** Nucleic Acids Res. 2006 May 22;34(9):2803-11.

### Abstracts:

- 1. Strain-specific penetrance and chromosome copy number variations in a mouse model for neuroblastoma. Christopher S. Hackett, J. Graeme Hodgson, Jian-Hua Mao, Denise Lind, Natalie Blades, Gary Churchill, Javed Khan, Pui-Yan Kwok, Allan Balmain, and William A. Weiss. AACR Mouse Models of Cancer Conference October 25-28, 2006.
- 2. **Transposon-based somatic mutagenesis for cancer gene discovery.** Lara S. C ollier, D avid J. Adams, Laura E. Green, Eric P. Rahrmann, Michael N. Davies, Miechaleen D. Diers, Anthony J. Cox, Christopher S. Hackett, J. Graeme Hodgson, Adam J. Dupuy, N eal G. Copeland, N ancy A. Jenkins, William A. Weiss, Allan Bradley, Paul C. Marker and David A. Largaespada. AACR Mouse Models of Cancer Conference October 25-28, 2006.
- 3. Structure-Based Prediction of Insertion-Site Preferences into Chromosomes of Vectors used for Gene Therapy. P.B. Hackett, C.S. Hackett, and A.M. Geurts A merican Society for Gene Therapy, 2007.
- 4. Sleeping Beauty insertional mutagenesis to identify genetic events in breast cancer progression. Christopher S Hackett, Lara S. Collier, Adam J. Dupuy, David A. Largaespada, and William A. Weiss Beckman Center for Transposon Research, Minneapolis, MN, June 2007
- 5. **Sleeping Beauty insertional mutagenesis to identify genetic events in breast cancer progression.** Christopher S Hackett, Lara S. Collier, Adam J. Dupuy, David A. Largaespada, and William A. Weiss. AACR Advances in Breast Cancer Research, San Diego, CA, October 2007.
- 6. Sleeping Beauty insertional mutagenesis and genetic linkage mapping identify loci governing tumor susceptibility in a mouse model for neuroblastoma. Christopher S. Hackett, Timothy K. Starr, Lara S. Collier, Gary Churchill, Fernando Pardo-Manuel de Villena, Javed Khan, Pui-Yan Kwok, David Largaespada, Allan B almain, a nd W illiam A. W eiss. A dvances i n N euroblastoma R esearch, Chiba, Japan, May 2008.
- 7. Chromosome Engineering and Sleeping Beauty insertional mutagenesis to identify 1p tumor suppressors and other genetic events in breast cancer progression. Christopher S Hackett, Timothy K. S tarr, Lara S. C ollier, A dam J. D upuy, Nigel K illeen, Zena W erb, D avid A. Largaespada, and William A. Weiss. DOD Era of Hope Meeting, Baltimore, MD June 2008.

### Awards:

AACR Scholar-in-Training Travel Award (AstraZeneca), AACR Mouse Models of Cancer Conference October 25-28, 2006.

### **CONCLUSION:**

As of the previous a nnual report, we have de-emphasized generating a mosue knoc kout of the 1p36 region, in light of numerous unforeseen technical difficulties and the failure of a nother group to see breast tumors in a similar system. As described last year, we have also acquired a wide range of tools to express the SB11 transposase in breast tissue; two additional mouse constructs, and 3 novel retroviral viral constructs. As of last year, we had generated as significant cohort of mice and have isolated over 40 tumors. We sequenced insertion sites from 11 of these tumors, and have seen indications of common insertion sites. However, most of these insertion sites were also seen in normal spleen tissue, suggesting these insertions did not arise in the mammary gland and did not drive tumorigenesis. A dditionally, tumors did not express transposase, and ove rall tumor ons et was not significantly accelerated in transposon-bearing mice. We then tried next-generation Sleeping Beauty expression mice. However, these mice either did not express transposase at high enough levels to accelerate mammary tumors, or expressed transposase in the hematopoietic compartment and succumbed to leukemia (or both).

We have thus adopted a lentivirus-based system in which we isolate mammary epithelial cells carrying the transposon, transduce the SB transposase with a lentivirus, and transplant the cells into donor mice. This system eliminates the possibility of expression in the hematopoietic compartment while allowing high levels of transposase expression in mammary epithelial cells. S ince this strategy has been only recently characterized and is technically more difficult than breeding multiple genetically engineered mice, we have established the ability to reconstitute mammary glands with transduced and transplanted mammary epithelial cells. We are currently observing the transplant recipient mice for tumor formation, which w ill provide proof of principle in the lentivirally-activated transposon-based insertional mutagenesis strategy in the mammary gland. This approach should provide a valuable tool with which to dissect various pathways in breast cancer.

### **REFERENCES:**

Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA. CHD5 is a tumor suppressor at human 1p36. Cell. 2007 Feb 9;128(3):459-75.

Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005 Jul 14;436(7048):272-6.

Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell. 2008 Jan 10;2(1):90-102.

### **APPENDICES:**

None.

### **SUPPORTING DATA:**

Embedded in text